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Structural Basis for Allosteric Regulation of the
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is at 8 mM, which is comparable to normal plasma glu-
cose levels, thus guaranteeing optimal responsiveness
at physiological glucose levels. However, the molecular
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mechanism of this glucose sensor has yet to be eluci-Banyu Tsukuba Research Institute in
dated, although allosteric kinetics have been extensivelycollaboration with Merck Research Laboratories
studied and structural analyses have been performedOkubo 3, Tsukuba
in several other allosteric enzymes (Kantrowitz and Lips-Ibaraki 300-2611
comb, 1988; Barford and Johnson, 1989; Schirmer andJapan
Evans, 1990; Iwata et al., 1994; Mattevi et al., 1996;
MacRae et al., 2002). For these oligomeric enzymes,
the active sites on several subunits are activated andSummary
inactivated in a concerted manner (Monod et al., 1965),
but such a mechanism does not appear to be employed
Glucokinase is a monomeric enzyme that displays a by glucokinase, because glucokinase is monomeric en-
low affinity for glucose and a sigmoidal saturation zyme with a single active site (Cardenas et al., 1978;
curve for its substrate, two properties that are impor- Connolly and Trayer, 1979). Several potential mecha-
tant for its playing the role of a glucose sensor in nisms for cooperativity of glucokinase have been pro-
pancreas and liver. The molecular basis for these two posed (Cornish-Bowden and Cardenas, 1987), but none
properties is not well understood. Herein we report has been proven, due to the lack of a crystal structure
the crystal structures of glucokinase in its active and for glucokinase, although the various conformations of
inactive forms, which demonstrate that global confor- yeast hexokinase and human hexokinase I have been
mational change, including domain reorganization, is determined (Anderson et al., 1978; Bennett and Steitz,
induced by glucose binding. This suggests that the 1978; Aleshin et al., 1998a, 1998b, 2000; Rosano et al.,
positive cooperativity of monomeric glucokinase 1999). The crystal structures of yeast hexokinase indi-
obeys the “mnemonical mechanism” rather than the cated that binding of glucose induced the conforma-
well-known concerted model. These structures also tional change from an open form to a closed form. Simi-
revealed an allosteric site through which small mole- lar conformational change was observed in crystal
cules may modulate the kinetic properties of the en- structures of hexokinase I, which is a glucokinase iso-
zyme. This finding provided the mechanistic basis for zyme and exhibits a high degree of sequence homology
activation of glucokinase as a potential therapeutic (54.4%). However, this structural information gave no
approach for treating type 2 diabetes mellitus. insight into the positive cooperativity of glucokinase,
because yeast hexokinase and human hexokinase I do
not exhibit sigmoidal dependency for glucose (KatzenIntroduction
and Schimke, 1965; Magnani et al., 1992). In this report,
we successfully analyzed the crystal structures of hu-Glucokinase (hexokinase IV or D) is a cytoplasmic en-
man glucokinase in both its active and inactive forms.zyme that phosphorylates glucose and triggers glucose
Substrate binding to the active site induced a globalutilization and metabolism. Glucokinase expressed in
alteration in enzyme conformation, which can accountliver and pancreas is thought to be a component of
for the allosteric properties of monomeric glucokinase.the glucose sensor controlling plasma glucose levels;
These data provide new insight into the structural mech-glucose-mediated activation of the enzyme in pancre-
anisms by which glucokinase is able to function as aatic  cells ultimately stimulates insulin secretion, while
glucose sensor.that in liver enhances hepatic glucose uptake and glyco-
Glucokinase plays an important role in the regulationgen synthesis (Van Schaftingen et al., 1994; Matschinsky
of glucose metabolism and thus represents a novel mo-et al., 1998). Both of these effects in turn reduce plasma
lecular target for drug development in type 2 diabetesglucose levels. The critical role of glucokinase in glucose
(Matschinsky, 2002; Grimsby et al., 2003). We recentlyhomeostasis is indicated by enzyme variants observed
identified small molecule synthetic activators that acti-in human subjects. Glucokinase variants with decreased
vated glucokinase and decreased blood glucose levelsactivity are associated with maturity-onset diabetes of
in several murine models of diabetes. The crystal struc-
the young type 2 (MODY-2) (Vionnet et al., 1992),
tures clearly showed that one of these activators binds
whereas variants with increased activity result in mild
to an allosteric site in the active form of glucokinase
hypoglycemia and increased glucose tolerance (Glaser and allosterically activates the enzyme. The data from
et al., 1998; Christesen et al., 2002). the current study should provide valuable information
The role of glucokinase as a glucose sensor is due for the development of novel glucokinase activators as
its allosteric properties. The activity of glucokinase ex- a new treatment for diabetes.
hibits a sigmoidal glucose dependency instead of the
Michaelis-Menten hyperbolic dependency of nonallo- Results and Discussion
steric enzymes (Storer and Cornish-Bowden, 1976). The
inflexion point on the sigmoidal glucose saturation curve Structure Determination of Human Glucokinase
In order to elucidate the molecular mechanism of the
allosteric regulation of glucokinase, we analyzed the*Correspondence: kenji_kamata@merck.com
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compound A, the Hill coefficient was decreased from
1.78 to 1.11, and the S0.5 value for glucose was de-
creased from 8 mM to 0.6 mM. At the same time, Vmax
was increased by 1.6-fold. To determine the inactive
conformation of glucokinase, we used GK(1-15) due
to its superior production of crystals. The crystal struc-
tures of GK(1-11) and GK(1-15) were analyzed at reso-
lutions of 2.3 A˚ and 3.4 A˚, respectively (Table 1).
Active Conformation of Glucokinase
The crystal structure of GK(1-11) in complex with glu-
cose and compound A reveals a palm shape (Figure
2A). The polypeptide chain is composed of 448 amino
acid residues that are distinctly folded into two domains
of unequal size; the large and small domains. These are
separated by a deep cleft, which forms the active site
for phosphorylation, and an  anomer of the glucose
molecule was observed to be bound to this active site
in GK(1-11). The electron density of compound A was
identified in an allosteric site at the interface between
the two domains.
The folding pattern observed in crystal structure of
GK(1-11) is identical to that of hexokinase I (Aleshin
et al., 1998a, 1998b, 2000; Rosano et al., 1999). Hexoki-
nase I is an isozyme of glucokinase and is expressed
mainly in the brain. The molecular weight of hexokinase
I is approximately twice that of glucokinase and is proba-
bly the result of gene duplication. Although the N-ter-
minal and C-terminal halves of hexokinase I show 49.9%
and 54.4% sequence identity with glucokinase, respec-
tively, the enzymatic activity of hexokinase I does not
Figure 1. Synthetic Activator of Glucokinase exhibit a sigmoidal glucose response, and this is also
true of hexokinase II and III (Katzen and Schimke, 1965;(A) Chemical formula of compound A, N-Thiazol-2-yl-2-amino-4-
fluoro-5-(1-methylimidazol-2-yl)thiobenzamide (inset), and the ef- Magnani et al., 1992). The crystal structures of hexoki-
fect of compound A on glucokinase enzymatic activity at 0.5 mM nase I indicate that binding of glucose to the center cleft
glucose concentration. induces a domain rotation from an open form to a closed
(B) Rate versus glucose concentration plot in the absence (solid
form in the same manner as is observed with yeastcircle) and presence of compound A (solid square, 30 M). The
hexokinase (Bennett and Steitz, 1978). When compareddata were fit to Hill equation. The graph shows actual data points
with hexokinase I, the spatial relationship between the(symbols) and the best-fit line.
large and small domains of GK(1-11) complexed with
glucose and compound A corresponds to the closed
form. As shown in Figure 3A, GK(1-11) and thecrystal structures of human glucokinase in both its ac-
tive and inactive forms. For crystallization, we deleted C-terminal half of the closed form of hexokinase I show
very similar structures in which the root-mean-squaredthe 11 or 15 N-terminal residues of hepatic glucokinase
in order to reduce structural flexibility. Hepatic glucoki- difference of C atoms of the two structures is 1.09 A˚.
The glucose binding site is located in the interdomainnase differs from pancreatic  cell glucokinase in the
15 N-terminal residues as a result of the alternative splic- cleft and is composed of residues of the large domain
(Glu256 and Glu290), the small domain (Thr168 anding of its mRNA, but both forms possess similar enzy-
matic properties (Tanizawa et al., 1991; Nishi et al., Lys169), and connecting region II (Asn204 and Asp205)
(Figure 4A). In comparison with the glucose binding site1992). The deletion mutants glucokinase GK(1-11) and
GK(1-15) showed similar values for S0.5 (concentration of hexokinase I, we were unable to identify any structural
differences that might account for the low affinity forof glucose at which glucokinase shows the half activity
of Vmax), Vmax, and Hill coefficient as wild-type gluco- glucose.
Although the closed form of glucokinase is almostkinase.
To determine the active conformation of glucokinase, identical to that of hexokinase I, a substantial difference
is seen in the region between Ser64 and Gly72 of GK(1-we cocrystallized GK(1-11) with glucose and a syn-
thetic activator, compound A (Figure 1A). Compound A 11) (Figure 3A). This region corresponds to connecting
region I and represents a flexible structure that is ex-is a potent activator with equal activity toward deletion
mutants and wild-type glucokinase. This compound posed to the solvent (Figure 4B). In contrast, the corre-
sponding region of hexokinase I forms a rigid structure.changes the shape of the glucose saturation curve from
sigmoidal to a Michaelis-Menten hyperbolic curve and The allosteric site is located near this glucokinase-spe-
cific structure and is surrounded by connecting regionincreases Vmax (Figure 1B). In the presence of 30 M of
Crystal Structures of Human Glucokinase
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Table 1. Data Collection Parameters and Refinement Statistics
Crystal Complex form Free form
Source PF BL6B Spring-8 BL32B2
Wavelength 1.000 A˚ 1.000 A˚
Resolution (A˚) 2.3 (2.38–2.3) 3.4 (3.58–3.4)
Total no. of observations 135,203 78,693
No. of unique observations 27,916 12,839
Completeness (%) 98.5 (96.1) 100.0 (100.0)
Rsym a (%) 3.3 (12.8) 8.0 (21.4)
I/(I) 31.3 (4.2) 6.8 (3.3)
Refinement statisticsb
Resolution (A˚) 50–2.3 50–3.4
No. of reflections in refinementc 26,981 12,436
No. of protein atoms 3691 3326
No. of atoms in ligands 35 0
No. of solvent atoms 149 H2O, 1 Na 7 H2O, 2 SO42	, 1 Na
Rworkingd (%) 23.2 23.8
Rfreed(%) 27.4 30.6






Bond lengths (A˚) 0.006 0.010
Bond angles (
) 1.16 1.23
a Rsym is the unweighted R values on I of symmetry-related reflections (hkl |Ihkl 	 Ihkl |/hklIhkl).
b Residues in the disordered region were eliminated from the model: 155–179 of the free form.
c Only reflections with |Fobs|  2  were used in the refinement.
d Rworking  hkl |Fobshkl 	 Fcalchkl|/hkl |Fobshkl |, for all reflections 2. Rfree is calculated from reflections not used in model refinement.
I, the large domain (1 strand and 5 helix), and the tween the two domains in the super-open form. As a
result, the interface between the large and small do-small domain (13 helix) (Figure 3B). Compound A
makes hydrophobic interactions with Val452 and Val455 mains also differs from that of the closed form. In the
closed form, glucose binds to the bottom of the deepon the 13 helix of the small domain. At the same time,
compound A interacts with residues in the large domain, interdomain cleft, and one rim of the glucose binding
pocket is formed by residues 157–179 of the small do-hydrogen bonding with Arg63 and Tyr215 and making
hydrophobic interactions with Val62, Met210, Ile211, main (Figure 4A). However, due to domain rotation and
disorder of residues 157–179, the glucose binding siteTyr214, and Met235 (Figure 4B). The molecular details
of compound A binding provide us with useful informa- is exposed to the solvent in the super-open form (Figure
4C). Since several important residues for enzymatic ac-tion for designing the next generation of activators with
improved properties, although the activation mecha- tivity are missing from this site, the super-open form of
glucokinase must be inactive, even if glucose was ablenism of compound A is still not clear based solely on
the structure of the active conformation because the to bind to the imperfect active site with low affinity. The
side chain of Asp205 in connecting region II is orientedallosteric site is approximately 20 A˚ away from the active
site. in the opposite direction when compared to the closed
form, and interaction between Asp205 and glucose may
trigger the conformational change to the closed form.Inactive Conformation of Glucokinase
Free form GK(1-15) showed a very different overall The structure of the allosteric site is also changed
(Figure 4D). Connecting region I shows a rigid turn struc-conformation (Figure 2B). The structure of the large do-
main was almost the same as that of complexed GK(1- ture instead of the loose structure seen in the closed
form, and the 13 helix is released from the small do-11), in which the root-mean-squared difference of C
atoms is 0.93 A˚. However, the orientation and organiza- main. Thus, the binding site of compound A is com-
pletely absent from the super-open form.tion of the small domain differed substantially. The main
part of the small domain was rotated about 99
 when
compared to the closed form. Because the spatial rela- Conformational Change between Active
and Inactive Formstionship between the two domains is also different from
that of open form hexokinase I, we referred to the struc- The two crystal structures indicated that glucokinase
undergoes a much larger conformational change thanture of free form glucokinase as the “super-open form.”
Surprisingly, the organization of the small domain was hexokinase I during the catalytic cycle, although the
active conformations (closed form) are almost identical.also different in the super-open form. As shown in Figure
2A, the 13 helix, which is the C-terminal region of glu- We analyzed the conformational change of glucokinase
by comparing it with that of hexokinase I (Figure 5).cokinase, is part of the small domain in the closed form,
but it was released from the small domain and lies be- In the closed form, small domains of glucokinase and
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Figure 2. Overall Structures of Glucokinase
(A) Ribbon drawing of the GK(1-11) structure complexed with glucose (red, ball-and-stick model) and compound A (yellow, ball-and-stick
model). The spatial relationship of the large domain (blue) and the small domain (cyan) exhibited a closed form. The two domains are connected
by connecting regions I–III (green). The 13 helix (magenta) is included in the small domain of the closed form.
(B) Ribbon drawing of free form GK(1-15). The spatial relationship of two domains was designated the super-open form. The 13 helix is
released from the small domain in the super-open form. Figures were prepared with MOLSCRIPT (Kraulis, 1991) and Raster3D (Merritt and
Murphy, 1994).
hexokinase I show the same three-layer architectures parallel orientation relative to 5 helix of the large do-
main while the middle layer of the  sheet rotates by(Gerstein et al., 1994). The 13 helix is in the inner layer,
which forms the domain interface with the 5 helix of approximately 120
 relative to the 13 helix, if the
movements of both layers are combined. These slidingthe large domain. During the conformational change of
hexokinase I, the three layers of the small domain rotate movements require the breakage and reformation of
numerous interactions among the layers, which is notabout 12
 as a rigid body, with connecting regions I–III
acting a hinge (Aleshin et al., 1998a). In contrast, while necessary for the hinge movement observed in the
closed-open conformational change of hexokinase I.the core region of the middle and outer layers of glucoki-
nase rotate by 99
 as a rigid body, the inner layer of Therefore, the transition between closed and super-
open forms takes longer than the closed-open confor-glucokinase moves in a different direction by an approxi-
mately 70
 rotation. As a result, the 13 helix of the mational change, due to the larger energy barrier that
likely exists between the two conformations, even ifinner layer is completely released from the small domain,
although the three-layer architecture is conserved in the super-open form is more stable in the absence of
glucose.the super-open form. During this large conformational
change, the 13 helix moves from a perpendicular to a Structural differences in connecting region I between
Crystal Structures of Human Glucokinase
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Figure 3. Active Conformation of Glucokinase
(A) Stereo view of superposed C models of complex form glucokinase (blue and green) and the C-terminal half of closed form hexokinase
I (Aleshin et al., 2000) (red and orange). The structures of connecting region I are different for the two enzymes (green and orange).
(B) Schematic drawing of domain composition and secondary structure of GK (1-11) in complex with glucose and compound A. Glucokinase
is composed of the large domain (blue) and the small domain (cyan and magenta). Connecting regions I–III (green) connect the two domains.
The C-terminal region of glucokinase forms the 13 helix (magenta) and is included in the small domain of GK(1-11). The glucose binding
site (red circle) and an allosteric site (yellow oval) are positioned between two domains.
Figure 4. Structures of the Active Site and the Allosteric Site
(A) Glucose binding site of closed form glucokinase. Glucose binds to the bottom of the deep cleft between the large domain (blue) and the
small domain (cyan). E256, E290 (blue stick model) of the large domain, T168, K169 (cyan stick model) of the small domain, and N204, D205
(green stick model) of connecting region II (green) form hydrogen bonds with glucose (pink stick model).
(B) Stereo view of the allosteric site in closed form glucokinase. The allosteric site is located below connecting region I (green stick model).
Compound A (yellow stick model) forms hydrogen bonds with R63 and Y215 (blue stick model) and hydrophobically interacts with M210,
Y214 (blue stick model) of the 5 helix (blue ribbon model) and V452, V455 (magenta stick model) of the 13 helix (magenta ribbon model).
(C) Glucose binding site of super-open form glucokinase. The active site is exposed to solvent. Color coding is as described for Figure 4A.
(D) Stereo view of the allosteric site in super-open form glucokinase. Due to the conformational change of connecting region I and the 13
helix, compound A is unable to bind. Color coding is as described for Figure 4B.
The figure was prepared using the PyMOL Molecular Graphics System (DeLano Scientific LLC, San Carlos, CA; http://www.pymol.org).
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Figure 6. Kinetic Model of Glucokinase
Glucokinase appears to exist in three conformations and to have
two catalytic cycles. The ratio of two catalytic cycles is responsible
for the sigmoidal response to glucose. Although ordered process
in the slow cycle of glucokinase was indicated by isotope-exchange
Figure 5. Schematic Drawing of Conformational Changes in Glu- experiment, the addition of substrates in the fast cycle may be
cokinase and Hexokinase I random.
The small domains of glucokinase and hexokinase I exhibited three-
layer architecture; the inner layer of the 13 helix (magenta cylinder),
the middle layer of the  sheet (cyan plate or orange plate), and the also exist in an intermediate state, an open form similar
outer layer of the 2, 3, and 4 helices (cyan cylinders or orange
to that of hexokinase I, as indicated by the high degreecylinders). During the closed-super-open conformational changes
of sequence homology and its structural similarity withof glucokinase, the core region of the middle and outer layers rotates
closed form hexokinase I. In the open form, the center99
 around an axis perpendicular to the plane indicated by the “X.”
The inner layer moves in a different direction from the other two cleft would be sufficiently open to release glucose 6-phos-
layers due to the loose connecting region I. During the closed-open phate and to take in a new glucose molecule, while the
conformational change of hexokinase I, the three layers of the small 13 helix would maintain similar interactions with the
domain rotate 12
 as a rigid body due to the rigidity of connecting
5 helix and the middle layer of the small domain as inregion I, which tightly holds the 13 helix.
the closed form.
Mechanism of Positive Cooperativityglucokinase and hexokinase I explain why much larger
domain motion occurs in glucokinase. As shown in Fig- As described in previous sections, the crystal structures
of glucokinase clearly show a large conformationalure 4B, residues 64–72 of the closed glucokinase exhibit
a loose structure that is exposed to the solvent. Below change between the active form and the inactive form.
In addition, an intermediate open form is also expectedthis region, there is a large space in which a synthetic
activator may bind. The corresponding region of hexoki- based on analysis of domain movement. Based on this
assumption and the structural data, we have devisednase I forms a rigid structure that interacts with the 5
and 13 helices, and there is no space for compound a kinetic model of glucokinase that accounts for the
sigmoidal nature of its enzymatic activity with plasmaA to bind. During the conformational change in hexoki-
nase I, residues in connecting region I change their dihe- glucose level.
As shown in Figure 6, glucokinase may exist in threedral angles but keep their tightly packed structure. This
rigid structure in connecting region I restricts the sliding conformations, and the conformational changes be-
tween the open form and the super-open form are slowermovement of the13 helix and prevents the helix release
observed in glucokinase. In contrast, the 13 helix of steps than the closed-open conformational change ob-
served during glucose phosphorylation. Unless glucoseglucokinase is easily released from the small domain
because of the loose structure of connecting region I, is present, the majority of glucokinase remains in the
thermodynamically favorable super-open form. Whenthus facilitating a larger rotation of the small domain.
Although we have only succeeded in crystallizing the glucose binds to the super-open form, glucokinase un-
dergoes a conformational change to the open form. Thisclosed form and the super-open form, glucokinase may
Crystal Structures of Human Glucokinase
435
change may be triggered by interaction between Asp205 saturation curve from sigmoidal to a Michaelis-Menten
hyperbolic curve and also increase Vmax. From the crystaland glucose and, as indicated by the crystal structures,
may take longer than the enzymatic reaction itself. After structure of GK(1-11) in complex with glucose and
compound A, we identified an allosteric site and deter-the slow transition to the open form, the enzymatic reac-
tion is then carried out by changing to the closed form mined the binding mode of a synthetic allosteric activa-
tor. Taken together with the kinetic model proposedin the presence of ATP. After the reaction is completed,
glucokinase returns to its open form in order to release in the previous section, this structural information is
indicative of the activation mechanism of compound A.glucose 6-phosphate and ADP. Because the open form
slowly equilibrates with the super-open form, a large It is apparent that binding of compound A to the alloste-
ric site sterically inhibits the release of the 13 helixproportion of the glucokinase stays in the open form for
some time. If glucose binds to the open form during this from the small domain. As result, glucokinase is unable
to change to the super-open conformation and can existperiod, glucokinase re-enters the catalytic cycle. If this
does not happen, glucokinase returns to the super-open only in the open or closed forms even at low concentra-
tions of glucose, as is observed for hexokinase I. Asform. In other words, glucokinase has two catalytic cy-
cles: a “slow cycle” and a “fast cycle.” The ratio of discussed above, the slow transition step between the
inactive and active forms is critical for the regulatorythe two cycles is determined by the concentration of
glucose and the length of time that glucokinase remains role of this monomeric cooperative enzyme; glucokinase
exhibits a Michaelis-Menten saturation curve in thein the open form. At low glucose concentrations, gluco-
kinase mainly uses the slow cycle with its low-affinity presence of compound A. Under this condition, glucoki-
nase shows high affinity for glucose in the same rangestructure, because the super-open form is more stable
than other forms in the absence of glucose. When glu- of other hexokinases that is consistent with very similar
active conformations. The increase Vmax is more difficultcose concentrations are sufficiently high, glucokinase
uses the fast cycle with its high-affinity structure. This to explain due to the lack of a crystal structure for the
open form. However, we speculate that the stabilizationshift of the major catalytic cycle explains the low affinity
and the sigmoidal saturation curve for glucose that glu- of the open form by compound A results in increased
Vmax values.cokinase exhibits, as well as its ability to regulate blood
glucose levels in vivo. Our theory of allosteric regulation also explains the
activated kinetic properties of several glucokinase mu-Among several proposed models for positive cooper-
ativity of a monomeric enzyme, the “mnemonical mech- tants. Two such mutants cause a metabolic disease,
persistent hyperinsulinemic hypoglycemia in infant (Gla-anism” is consistent with our model (Storer and Cornish-
Bowden, 1977). The mnemonical mechanism is based ser et al., 1998; Christesen et al., 2002). Patients have
a heterozygous mutation substituting methionine for va-on the concept that an enzyme “memorizes” the active
conformation after the catalytic reaction and subse- line at residue 455 (V455M) or substituting valine for
alanine at residue 456 (A456V). In addition, the syntheticquently “forgets” it some time afterwards. Isotope ex-
change studies supported this mechanism and indi- glucokinase mutant Y214A, in which tyrosine 214 is sub-
stituted with alanine, which is the corresponding residuecated that glucokinase follows a predominantly ordered
mechanism, with glucose binding first and glucose in hexokinase I, exhibited activated kinetic properties
(Moukil et al., 2000). Kinetic analysis of these three mu-6-phosphate released last (Gregoriou et al., 1981). Mou-
kil and colleagues postulated the existence of the super- tants shows substantially decreased S0.5 values (3.2, 2.5,
and 1.3 mM, respectively) from the 8 mM of wild-typeopen form and showed that the mnemonical mechanism
simulated the kinetic behavior of mutants and wild-type glucokinase (Christesen et al., 2002; Davis et al., 1999).
These residues are included in the binding site of com-glucokinase very well (Moukil and Van Schaftingen,
2001). In addition, several experiments demonstrated pound A (Figure 4B), and these mutations seem to inhibit
of the release of the 13 helix either as a result of theirthe existence of the slow transition step during the cata-
lytic cycle of glucokinase (Lin and Neet, 1990; Neet et bulkier side chains (V455M and A456V) or by decreasing
the flexibility of connecting region I (Y214A).al., 1990). Comparison with hexokinase I also provides
supporting evidence for the structural basis of coopera-
tivity. Hexokinase I shows a Michaelis-Menten hyper-
Regulation of Hepatic Glucokinase by Glucokinasebolic saturation curve for glucose, in spite of the very
Regulatory Proteinsimilar active structures. Because hexokinase I exists
The activity of hepatic glucokinase is also regulated byonly in the closed form or the open form and does not
glucokinase regulatory protein (GKRP). Several experi-exist in the super-open form due to differences in the
ments suggest that glucokinase is localized in the hepa-structure of connecting region I, hexokinase I uses the
tocyte nucleus as an inactive complex with GKRP atfast catalytic cycle at any glucose concentration. The
low plasma glucose levels, but is dissociated from thelack of a slow transition step results in a Michaelis-
complex at higher glucose levels and then is translo-Menten hyperbolic saturation curve for glucose.
cated into the cytoplasm (Shiota et al., 1999; De la Iglesia
et al., 2000). GKRP would likely be an allosteric inhibitor
of glucokinase that specifically binds to the super-openMechanism of Activation by Synthetic Activator
and Mutagenesis form of glucokinase. Mutation studies in Xenopus glucoki-
nase showed that two regions of glucokinase may be in-Allosteric activators for glucokinase as potential drugs
for type 2 diabetes have been pursued in recent years. cluded in the binding site of GKRP (Veiga-da-Cunha et al.,
1996). In the closed form, these two sites (Glu51Glu52Allosteric activators change the shape of the glucose
Structure
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Crystallization of Mutant Glucokinaseand His141Leu144) are separated by approximately
Crystals of glucokinase were grown by the hanging drop method.40 A˚, and the no-effect region (Val154 Asp158) is posi-
Glucokinase was dialyzed against 20 mM Tris-HCl, 50 mM NaCl, 5tioned between these two sites. In contrast, the two
mM Tris (2-carboxyethyl) phosphine hydrochloride solution (pH 7.5)
regions are much closer together (approximately 20 A˚) and concentrated to 10 mg/ml. For crystallization of the complex
in the super-open form of glucokinase. This supports form, glucose and compound A were added to the protein solution
so that final concentrations were 20 mM and 300 M, respectively.the idea that GKRP specifically binds to the super-open
A volume of 1.5–3.0 l of the resulting solution was combined withform of glucokinase. We are currently attempting to de-
an equal volume of a precipitant solution containing 28%–30% PEGtermine the structure of the glucokinase-GKRP complex
1500 and 0.1 M HEPES-NaOH (pH 6.6). The drops were equilibratedin order to identify the interactions between glucokinase
against 1.0 ml of the precipitant solution. Prismatic crystals of length
and GKRP. 0.5–0.8 mm and width 0.2–0.3 mm grew in a week. The crystals
In summary, the crystal structures of glucokinase re- belonged to the P6522 space group (a  b  79.86 A˚, c  322.22 A˚)
with a monomer in an asymmetric unit.vealed the structural basis of the glucose sensor, which
Crystals of the free form were obtained by using a precipitantis an essential component for glucose homeostasis. Fur-
solution containing 1.5–1.6 M ammonium sulfate, 50 mM sodiumthermore, human glucokinase is the first monomeric al-
chloride, and 0.1 M Bicine-NaOH (pH 8.7). Rod shaped crystals oflosteric enzyme of which the regulation mechanism is
length 0.5–0.8 mm and width 0.03–0.07 mm grew in a week. The
clearly explained by structural information. This finding crystals belonged to the P6522 space group (a  b  103.18 A˚, c 
indicates that the mnemonical mechanism is also impor- 281.02 A˚) with a monomer in an asymmetric unit.
tant for metabolic regulation of allosteric enzymes as
Data Collection, Structure Determination, and Refinementwell as the well-known concerted model. With regard to
X-ray diffraction data of the complex form at 100 K were collectedpotential applications, the allosteric site of glucokinase
at BL6B beam line of the Photon Factory in KEK and processedsuggests the possibility that small synthetic activators
with DENZO and SCALEPACK software (Otwinowski and Minor,
may act as new drugs to treat type 2 diabetes, although 1997). X-ray diffraction data of the free form at 100 K were collected
endogenous allosteric activators have yet to be iden- at the BL32B2 beam line in Spring-8 and processed with MOSFLM
tified. (Leslie, 1998) and SCALA software (Evans, 1993; CCP4, 1994). Mea-
surement parameters and derived data are given in Table 1. Struc-
tures were solved by the molecular replacement method using theExperimental Procedures
AMORE program (Navaza, 1994) of the CCP4 package (CCP4, 1994).
For structure determination of the complex form, the structure ofConstruction of Human Hepatic Glucokinase Deletion Mutants
the C-terminal domain of human hexokinase I (Protein Data BankThe deletion mutants GK(1-11) and GK(1-15) were constructed
identification: 1CZA; Aleshin et al., 2000) was used as the model.by polymerase chain reaction (PCR)-based site-directed mutagene-
For structure determination of the free form, the large domain andsis. To insert a HindIII recognition site and initiation codon sequence
the small domain of complex form glucokinase were separately usedjust before Ala12 or Val16, the primer 5-GTCACAAGGAGCCAGAAG
as models. Model building, electron density map calculation, andCTTATGGCCTTGACTCTGGTAG-3 or 5-CCAGGCCCAGACAGCC
model refinement were performed with CNX (Brunger et al., 1998)AAGCTTATGGTAGAGCAGATCC-3 was used with 5-GAAGCCC
(Accelrys Inc.) and O (Jones et al., 1991) programs. Crystal structuresCACGACATTGTTCCCTTCTGC-3 during PCR. From the PCR prod-
of the complex form and the free form were refined to an R valueucts, 1.2 kb fragments were excised using the newly introduced
of 23.2% (Rfree  27.4%) and an R value of 23.8% (Rfree  30.6%)HindIII site and a ClaI site and was used to replace the nonmutated
with good stereochemistry (Table 1).sequences in a pFLAG-CTC expression vector containing the human
wild-type liver glucokinase gene between the HindIII and EcoRI
Supplemental Datasites. Mutations were confirmed by sequencing the inserted DNA
Supplemental data, including the synthetic method of compound A,fragments.
is available at: http://www.structure.org/cgi/content/full/12/3/429/
DC1.
Expression and Purification of Mutant Glucokinase
E. coli strain DH5, transformed with mutant pFLAG-CTC vectors, Acknowledgments
was grown in LB medium at 37
C to an A600 of 0.8, and the tempera-
ture was then decreased to 25
C, and IPTG added to a final concen- We thank M. Yoshida, S. Nishimura, H. Morishima, T. Fukami, T.
tration of 0.4 mM. At 16–24 hr after induction, the cells were har- Iwama, H. Hosaka, S. Iwata, D. Moller, J. Becker, T. Kelly, and B.
vested and resuspended in buffer A (50 mM potassium phosphate Zhang for critical reading and discussions. We are also grateful to
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supernatant was dialysed against buffer A at a temperature of 4
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Pooled fractions of mutant glucokinase were purified on Glucos-
amine-Sepharose and Mono Q (Amersham Biosciences) columns, Received: September 9, 2003
as described previously (Miwa et al., 1990; Takeda et al., 1993). Revised: October 30, 2003
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